H.C. Wainwright upgraded Innate Pharma (IPHA) to Buy from Neutral with a $5 price target The company announced its intention to file an application with the FDA for an accelerated approval of lacutamab and initiate a Phase 3 study to evaluate the drug as a therapy for cutaneous T-cell lymphoma, the analyst tells investors in a research note. The firm recommends buying the stock’s recent weakness.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPHA: